false 0001760542 0001760542 2023-11-27 2023-11-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 27, 2023

 

HOOKIPA PHARMA INC.

(Exact name of  Registrant as Specified in Its Charter)

 

Delaware   001-38869   81-5395687

(State or Other Jurisdiction of
Incorporation)

  

(Commission
File Number)

  

(IRS Employer
Identification No.)

 

350 Fifth Avenue, 72nd Floor,

Suite 7240

  
New York, New York   10118
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of exchange on which registered
Common stock, $0.0001 HOOK The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 27, 2023, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the “Company”) changed the title of the Company’s current Chief Development Officer, Dr. Roman Necina, to Chief Operations Officer, effective January 1, 2024.

 

Roman Necina, Ph.D., has served as the Company’s Chief Development Officer since July 2022. Prior to that he was our Chief Technology Officer from November 2019 through June 2022. Dr. Necina’s biographical information is incorporated herein by reference from the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 13, 2023.

 

There are no arrangements or understandings pursuant to which Dr. Necina was selected for his position, other than his existing employment contract with the Company which remains unchanged.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  HOOKIPA Pharma Inc.
   
Date: December 1, 2023 By:   /s/ Joern Aldag
    Joern Aldag
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

v3.23.3
Cover
Nov. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 27, 2023
Entity File Number 001-38869
Entity Registrant Name HOOKIPA PHARMA INC.
Entity Central Index Key 0001760542
Entity Tax Identification Number 81-5395687
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Fifth Avenue, 72nd Floor,
Entity Address, Address Line Two Suite 7240
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10118
City Area Code +43
Local Phone Number 1 890 63 60
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001
Trading Symbol HOOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more HOOKIPA Pharma Charts.
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more HOOKIPA Pharma Charts.